An Evaluation of Cabozantinib for the Treatment of Renal Cell Carcinoma: Focus on Patient Selection and Perspectives

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma. Nat Rev Dis Primer. 2017;3(1):17009. doi:10.1038/nrdp.2017.9
   PubMed Web of Science ®Google Scholar
• Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10(12):2298–2308. doi:10.1158/1535-7163.MCT-11-0264
   PubMed Web of Science ®Google Scholar
• Tímár J, Döme B. Antiangiogenic drugs and tyrosine kinases. Anticancer Agents Med Chem. 2008;8(5):462–469. doi:10.2174/187152008784533035
   PubMed Web of Science ®Google Scholar
• Dj H, Lm E. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol off J Am Soc Clin Oncol. 2005;23:5. doi:10.1200/JCO.2005.06.081
   PubMed Web of Science ®Google Scholar
• Ravaud A, Digue L, Trufflandier N, Smith D. VEGFR TKI “resistance” or transient clinical insensitivity to VEGFR TKI in metastatic renal cell carcinoma. Ann Oncol off J Eur Soc Med Oncol. 2010;21(2):431–432. doi:10.1093/annonc/mdp548
   PubMed Web of Science ®Google Scholar
• Ravaud A, Gross-Goupil M. Overcoming resistance to tyrosine kinase inhibitors in renal cell carcinoma. Cancer Treat Rev. 2012;38(8):996–1003. doi:10.1016/j.ctrv.2012.01.003
   PubMed Web of Science ®Google Scholar
• Awad MM, Oxnard GR, Jackman DM, et al. MET Exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-met overexpression. J Clin Oncol off J Am Soc Clin Oncol. 2016;34(7):721–730. doi:10.1200/JCO.2015.63.4600
   PubMed Web of Science ®Google Scholar
• Shojaei F, Lee JH, Simmons BH, et al. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res. 2010;70(24):10090–10100. doi:10.1158/0008-5472.CAN-10-0489
   PubMed Web of Science ®Google Scholar
• Lee C, Whang YM, Campbell P, et al. Dual targeting c-met and VEGFR2 in osteoblasts suppresses growth and osteolysis of prostate cancer bone metastasis. Cancer Lett. 2018;414:205–213. doi:10.1016/j.canlet.2017.11.016
   PubMed Web of Science ®Google Scholar
• Smith DC, Smith MR, Sweeney C, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol off J Am Soc Clin Oncol. 2013;31(4):412–419. doi:10.1200/JCO.2012.45.0494
   PubMed Web of Science ®Google Scholar
• Smith MR, Sweeney CJ, Corn PG, et al. Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. J Clin Oncol off J Am Soc Clin Oncol. 2014;32(30):3391–3399. doi:10.1200/JCO.2013.54.5954
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, Phase 3 trial. Lancet Oncol. 2016;17(7):917–927. doi:10.1016/S1470-2045(16)30107-3
   PubMed Web of Science ®Google Scholar
• Nguyen L, Benrimoh N, Xie Y, Offman E, Lacy S. Pharmacokinetics of cabozantinib tablet and capsule formulations in healthy adults. Anticancer Drugs. 2016;27(7):669–678. doi:10.1097/CAD.0000000000000366
   PubMed Web of Science ®Google Scholar
• Lacy SA, Miles DR, Nguyen LT. Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib. Clin Pharmacokinet. 2017;56(5):477–491. doi:10.1007/s40262-016-0461-9
   PubMed Web of Science ®Google Scholar
• Nguyen L, Holland J, Mamelok R, et al. Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects. J Clin Pharmacol. 2015;55(11):1293–1302. doi:10.1002/jcph.526
   PubMed Web of Science ®Google Scholar
• Nguyen L, Holland J, Miles D, et al. Pharmacokinetic (PK) drug interaction studies of cabozantinib: effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK. J Clin Pharmacol. 2015;55(9):1012–1023. doi:10.1002/jcph.510
   PubMed Web of Science ®Google Scholar
• Cabometyx-epar-product-information.pdf. Available from: https://www.ema.europa.eu/en/documents/product-information/cabometyx-epar-product-information_en.pdf. Accessed May 23, 2022.
   Google Scholar
• Nguyen L, Holland J, Ramies D, et al. Effect of renal and hepatic impairment on the pharmacokinetics of cabozantinib. J Clin Pharmacol. 2016;56(9):1130–1140. doi:10.1002/jcph.714
   PubMed Web of Science ®Google Scholar
• Lacy S, Yang B, Nielsen J, Miles D, Nguyen L, Hutmacher M. A population pharmacokinetic model of cabozantinib in healthy volunteers and patients with various cancer types. Cancer Chemother Pharmacol. 2018;81(6):1071–1082. doi:10.1007/s00280-018-3581-0
   PubMed Web of Science ®Google Scholar
• Lacy S, Nielsen J, Yang B, Miles D, Nguyen L, Hutmacher M. Population exposure-response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma. Cancer Chemother Pharmacol. 2018;81(6):1061–1070. doi:10.1007/s00280-018-3579-7
   PubMed Web of Science ®Google Scholar
• Krens SD, van Erp NP, Groenland SL, et al. Exposure-response analyses of cabozantinib in patients with metastatic renal cell cancer. BMC Cancer. 2022;22(1):228. doi:10.1186/s12885-022-09338-1
   PubMed Web of Science ®Google Scholar
• Albiges L, Fléchon A, Chevreau C, et al. Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: results from the CABOREAL Early Access Program. Eur J Cancer Oxf Engl. 2021;142:102–111. doi:10.1016/j.ejca.2020.09.030
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Pal SK, McDermott DF, et al. A phase I study of cabozantinib (XL184) in patients with renal cell cancer. Ann Oncol off J Eur Soc Med Oncol. 2014;25(8):1603–1608. doi:10.1093/annonc/mdu184
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1814–1823. doi:10.1056/NEJMoa1510016
   PubMed Web of Science ®Google Scholar
• Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol off J Eur Soc Med Oncol. 2016;27(suppl 5):v58–v68. doi:10.1093/annonc/mdw328
   PubMed Web of Science ®Google Scholar
• Heng DYC, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol off J Am Soc Clin Oncol. 2009;27(34):5794–5799. doi:10.1200/JCO.2008.21.4809
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial. J Clin Oncol off J Am Soc Clin Oncol. 2017;35(6):591–597. doi:10.1200/JCO.2016.70.7398
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Hessel C, Halabi S, et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update. Eur J Cancer Oxf Engl. 2018;94:115–125. doi:10.1016/j.ejca.2018.02.012
   PubMed Web of Science ®Google Scholar
• George DJ, Hessel C, Halabi S, et al. Cabozantinib versus sunitinib for untreated patients with advanced renal cell carcinoma of intermediate or poor risk: subgroup analysis of the Alliance A031203 CABOSUN trial. Oncologist. 2019;24(11):1497–1501. doi:10.1634/theoncologist.2019-0316
   PubMed Web of Science ®Google Scholar
• Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol off J Eur Soc Med Oncol. 2019;30(5):706–720. doi:10.1093/annonc/mdz056
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277–1290. doi:10.1056/NEJMoa1712126
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1103–1115. doi:10.1056/NEJMoa1816047
   PubMed Web of Science ®Google Scholar
• Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116–1127. doi:10.1056/NEJMoa1816714
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384(9):829–841. doi:10.1056/NEJMoa2026982
   PubMed Web of Science ®Google Scholar
• Powles T, Choueiri TK, Burotto M, et al. Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma. J Clin Oncol. 2022;40(6_suppl):350. doi:10.1200/JCO.2022.40.6_suppl.350
   Web of Science ®Google Scholar
• Motzer R, Alekseev B, Rha SY, et al. CLEAR trial investigators. lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384(14):1289–1300. PMID: 33616314. doi:10.1056/NEJMoa2035716
   PubMed Web of Science ®Google Scholar
• Powles T; ESMO Guidelines Committee. Electronic address: [email protected]. Recent eUpdate to the ESMO clinical practice guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol off J Eur Soc Med Oncol. 2021;32(3):422–423. doi:10.1016/j.annonc.2020.11.016
   PubMed Web of Science ®Google Scholar
• Kwilas AR, Ardiani A, Donahue RN, Aftab DT, Hodge JW. Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine. J Transl Med. 2014;12(1):294. doi:10.1186/s12967-014-0294-y
   PubMed Web of Science ®Google Scholar
• Patnaik A, Swanson KD, Csizmadia E, et al. Cabozantinib eradicates advanced murine prostate cancer by activating antitumor innate immunity. Cancer Discov. 2017;7(7):750–765. doi:10.1158/2159-8290.CD-16-0778
   PubMed Web of Science ®Google Scholar
• Akalu YT, Rothlin CV, Ghosh S. TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy. Immunol Rev. 2017;276(1):165–177. doi:10.1111/imr.12522
   PubMed Web of Science ®Google Scholar
• Ocaña-Guzman R, Vázquez-Bolaños L, Sada-Ovalle I. Receptors that inhibit macrophage activation: mechanisms and signals of regulation and tolerance. J Immunol Res. 2018;2018:8695157. doi:10.1155/2018/8695157
   PubMed Web of Science ®Google Scholar
• Yang J, Yan J, Liu B. Targeting VEGF/VEGFR to modulate antitumor immunity. Front Immunol. 2018;9:978. doi:10.3389/fimmu.2018.00978
   PubMed Web of Science ®Google Scholar
• Vano YA, Ladoire S, Elaidi R, et al. First-line treatment of metastatic clear cell renal cell carcinoma: what are the most appropriate combination therapies? Cancers. 2021;13(21):5548. doi:10.3390/cancers13215548
   PubMed Web of Science ®Google Scholar
• Iacovelli R, Cartenì G, Sternberg CN, et al. Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort. Eur J Cancer Oxf Engl. 2013;49(9):2134–2142. doi:10.1016/j.ejca.2013.02.032
   PubMed Web of Science ®Google Scholar
• McGregor BA, Lalani AKA, Xie W, et al. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma. Eur J Cancer Oxf Engl. 2020;135:203–210. doi:10.1016/j.ejca.2020.05.009
   PubMed Web of Science ®Google Scholar
• Auvray M, Auclin E, Barthelemy P, et al. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma. Eur J Cancer Oxf Engl. 2019;108:33–40. doi:10.1016/j.ejca.2018.11.031
   PubMed Web of Science ®Google Scholar
• Barata PC, De Liano AG, Mendiratta P, et al. The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma. Br J Cancer. 2018;119(2):160–163. doi:10.1038/s41416-018-0104-z
   PubMed Web of Science ®Google Scholar
• Navani V, Wells C, Boyne DJ, et al. CABOSEQ: the efficacy of cabozantinib post up-front immuno-oncology combinations in patients with advanced renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). J Clin Oncol. 2022;40(6_suppl):318. doi:10.1200/JCO.2022.40.6_suppl.318
   Web of Science ®Google Scholar
• Albiges L, Schmidinger M, Taguieva-Pioger N, Perol D, Grünwald V, Guemas E. CaboPoint: a Phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma. Future Oncol Lond Engl. 2021. doi:10.2217/fon-2021-1006
   PubMed Web of Science ®Google Scholar
• Stern PH, Alvares K. Antitumor agent cabozantinib decreases RANKL expression in osteoblastic cells and inhibits osteoclastogenesis and PTHrP-stimulated bone resorption. J Cell Biochem. 2014;115(11):2033–2038. doi:10.1002/jcb.24879
   PubMed Web of Science ®Google Scholar
• Haider MT, Hunter KD, Robinson SP, et al. Rapid modification of the bone microenvironment following short-term treatment with Cabozantinib in vivo. Bone. 2015;81:581–592. doi:10.1016/j.bone.2015.08.003
   PubMed Web of Science ®Google Scholar
• Bersanelli M, Buti S, Ghidini A, Tiseo M, Petrelli F. A metanalysis on cabozantinib and bone metastases: true story or commercial gimmick? Anticancer Drugs. 2020;31(3):211–215. doi:10.1097/CAD.0000000000000883
   PubMed Web of Science ®Google Scholar
• Peverelli G, Raimondi A, Ratta R, et al. Cabozantinib in renal cell carcinoma with brain metastases: safety and efficacy in a real-world population. Clin Genitourin Cancer. 2019;17(4):291–298. doi:10.1016/j.clgc.2019.05.002
   PubMed Web of Science ®Google Scholar
• Hirsch L, Martinez Chanza N, Farah S, et al. Clinical activity and safety of cabozantinib for brain metastases in patients with renal cell carcinoma. JAMA Oncol. 2021;7(12):1815–1823. doi:10.1001/jamaoncol.2021.4544
   PubMed Web of Science ®Google Scholar
• Martínez Chanzá N, Xie W, Asim Bilen M, et al. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. Lancet Oncol. 2019;20(4):581–590. doi:10.1016/S1470-2045(18
   PubMed Web of Science ®Google Scholar
• Fléchon A, Chevreau CM, Topart D, et al. 732P Cabozantinib in non-clear cell metastatic renal cell carcinoma and sarcomatoid renal cell carcinoma: real-world data from the CABOREAL study. Ann Oncol. 2020;31:S572–S573. doi:10.1016/j.annonc.2020.08.804
   Web of Science ®Google Scholar
• Pal SK, Tangen C, Thompson IM, et al. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, Phase 2 trial. Lancet Lond Engl. 2021;397(10275):695–703. doi:10.1016/S0140-6736(21)00152-5
   PubMed Web of Science ®Google Scholar
• Lee CH, Voss MH, Carlo MI, et al. Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: results of a phase 2 trial. J Clin Oncol. 2021;39(15_suppl):4509. doi:10.1200/JCO.2021.39.15_suppl.4509
   Web of Science ®Google Scholar
• Fogli S, Porta C, Del Re M, et al. Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs. Cancer Treat Rev. 2020;84:101966. doi:10.1016/j.ctrv.2020.101966
   PubMed Web of Science ®Google Scholar
• Rassy E, Cerbone L, Auclin E, et al. The Effect of Concomitant Proton Pump Inhibitor and Cabozantinib on the Outcomes of Patients with Metastatic Renal Cell Carcinoma. Oncologist. 2021;26(5):389–396. doi:10.1002/onco.13711
   PubMed Web of Science ®Google Scholar
• Roodhart JM, Langenberg MH, Witteveen E, Voest EE. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr Clin Pharmacol. 2008;3(2):132–143. doi:10.2174/157488408784293705
   PubMedGoogle Scholar
• Schmidinger M, Danesi R. Management of adverse events associated with cabozantinib therapy in renal cell carcinoma. Oncologist. 2018;23(3):306–315. doi:10.1634/theoncologist.2017-0335
   PubMed Web of Science ®Google Scholar
• Wasa J, Sugiura H, Kozawa E, Kohyama K, Yamada K, Taguchi O. The tumor suppressive effect of angiotensin II type 1 receptor antagonist in a murine osteosarcoma model. Anticancer Res. 2011;31(1):123–127.
   PubMed Web of Science ®Google Scholar
• McGregor B, Mortazavi A, Cordes L, Salabao C, Vandlik S, Apolo AB. Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: a review. Cancer Treat Rev. 2022;103:102333. doi:10.1016/j.ctrv.2021.102333
   PubMed Web of Science ®Google Scholar
• DosingandAdministrationGuide.pdf. Available from: https://www.cabometyxhcp.com/sites/default/files/2021-03/DosingandAdministrationGuide.pdf. Accessed April 24, 2022.
   Google Scholar
• Colomba E, Alves Costa Silva C, Le Teuff G, et al. 965P - Weight loss is an underestimated adverse event with cabozantinib in patients with metastastic renal cell carcinoma (mRCC). Ann Oncol. 2019;30:v390–v391. doi:10.1093/annonc/mdz249.061
   Web of Science ®Google Scholar
• Donskov F, Motzer RJ, Voog E, et al. Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma. Eur J Cancer Oxf Engl. 2020;126:1–10. doi:10.1016/j.ejca.2019.10.032
   PubMed Web of Science ®Google Scholar
• Gross-Goupil M, Fléchon A, Mourey L, et al. 722P Cabozantinib in elderly patients: results from a subanalysis of the CABOREAL study. Ann Oncol. 2020;31:S566–S567. doi:10.1016/j.annonc.2020.08.794
   Web of Science ®Google Scholar
• Blevins DP, Dadu R, Hu M, et al. Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer. Thyroid off J Am Thyroid Assoc. 2014;24(5):918–922. doi:10.1089/thy.2012.0598
   PubMed Web of Science ®Google Scholar
• Quhal F, Mori K, Bruchbacher A, et al. First-line immunotherapy-based combinations for metastatic renal cell carcinoma: a systematic review and network meta-analysis. Eur Urol Oncol. 2021;4(5):755–765. doi:10.1016/j.euo.2021.03.001
   PubMed Web of Science ®Google Scholar
• McDermott DF, Huseni MA, Atkins MB, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018;24(6):749–757. doi:10.1038/s41591-018-0053-3
   PubMed Web of Science ®Google Scholar
• Vano Y, Elaidi RT, Bennamoun M, et al. LBA25 Results from the phase II biomarker driven trial with nivolumab (N) and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer (m-ccRCC) patients (pts): the BIONIKK trial. Ann Oncol. 2020;31:S1157. doi:10.1016/j.annonc.2020.08.2254
   Web of Science ®Google Scholar
• Denize T, Farah S, Cimadamore A, et al. Biomarkers of angiogenesis and clinical outcomes to cabozantinib and everolimus in patients with metastatic renal cell carcinoma from the phase III METEOR trial. Clin Cancer Res off J Am Assoc Cancer Res. 2022;28(4):748–755. doi:10.1158/1078-0432.CCR-21-3088
   PubMed Web of Science ®Google Scholar
• Zucca LE, Morini Matushita MA, da Silva Oliveira RJ, et al. Expression of tyrosine kinase receptor AXL is associated with worse outcome of metastatic renal cell carcinomas treated with sunitinib. Urol Oncol. 2018;36(1):11.e13–11.e21. doi:10.1016/j.urolonc.2017.09.003
   PubMed Web of Science ®Google Scholar
• Powles T, Choueiri TK, Motzer RJ, et al. Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. BMC Cancer. 2021;21(1):904. doi:10.1186/s12885-021-08630-w
   PubMed Web of Science ®Google Scholar
• Pal SK, McGregor B, Suárez C, et al. Cabozantinib in combination with atezolizumab for advanced renal cell carcinoma: results from the COSMIC-021 study. J Clin Oncol off J Am Soc Clin Oncol. 2021;39(33):3725–3736. doi:10.1200/JCO.21.00939
   PubMed Web of Science ®Google Scholar
• Bilen MA, Liu Y, Nazha B, et al. Phase 2 study of neoadjuvant cabozantinib in patients with locally advanced non-metastatic clear cell renal cell carcinoma.. J Clin Oncol. 2022;40(6_suppl):340. doi:10.1200/JCO.2022.40.6_suppl.340
   Web of Science ®Google Scholar